Prognostic Significance of Interleukin‐34 (IL‐34) in Patients With Chronic Heart Failure With or Without Renal Insufficiency

Abstract

Background Renal dysfunction, commonly associated with cardiac dysfunction, has predictive value for adverse long‐term outcomes in heart failure ( HF ). We previously identified a novel renal biomarker, interleukin‐34 ( IL ‐34), elevated in HF patients and associated with kidney dysfunction and coronary artery disease during HF . However, the prognostic value of IL ‐34 in HF remains unclear, so that the present study aimed to determine it. Methods and Results This prospective, observational study included 510 consecutive HF patients with their serum IL ‐34 as well as other variables measured at baseline, and they were followed up for 2 years. The primary end point was a composite of cardiovascular death or a first HF hospitalization, with cardiovascular death, HF hospitalization, and all‐cause mortality as secondary outcomes. There was a significant and gradual increase in risk as IL ‐34 increased, determined by log‐rank tests with Kaplan–Meier curves. Serum IL ‐34 was also a significant prognostic predictor of the primary end point (1.301 [1.115–1.518]; P =0.001), cardiovascular death (1.347 [1.096–1.655]; P =0.005), HF hospitalization (1.234 [1.018–1.494]; P =0.032), and all‐cause mortality (1.343 [1.115–1.618]; P =0.002) in HF as per SD increase in the log IL ‐34 level after adjusting for age, sex, traditional risk factors, and N‐terminal pro‐brain natriuretic peptide. Especially, IL ‐34 had a more‐significant prognostic value in HF patients with kidney impairment than those without. Conclusions IL ‐34 is a significant predictor of cardiovascular death, HF hospitalization, and all‐cause mortality in chronic HF , especially when concomitant with renal dysfunction. Serum IL ‐34 measurement may provide new insights linking kidney impairment to poor HF outcomes beyond other renal markers.